TGF-β signaling in vascular biology and dysfunction

Cell Research

Volumn 19, Issue 1, 2009, Pages 116-127

  Goumans, Marie José ^a   Liu, Zhen ^a   Ten Dijke, Peter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; BMP; Marfan syndrome; Pre eclampsia; Pulmonary hypertension; Smad; TGF

Indexed keywords

BONE MORPHOGENETIC PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANGIOGENESIS; ANIMAL; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; HYPERTENSION, PULMONARY; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 58149230979     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2008.326     Document Type: Review

References (117)

1. Heldin C-H, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390:465-471.
2. Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003; 113:685-700.
3. Schmierer B, Hill CS. TGFβ-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007; 8:970-982.
4. ten Dijke P, Arthur HM. Extracellular control of TGFβ signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8:857-869.
5. Oh SP, Seki T, Goss KA, et al. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 2000; 97:2626-2631.
6. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J 2002; 21:1743-1753.
7. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008; 11:79-89.
8. López-Casillas F, Wrana JL, Massagué J. Betaglycan presents ligand to the TGFβ signaling receptor. Cell 1993; 73:1435-1444.
9. Del Re E, Babitt JL, Pirani A, Schneyer AL, Lin HY. In the absence of type III receptor, the transforming growth factor (TGF)-β type II-B receptor requires the type I receptor to bind TGF-β2. J Biol Chem 2004; 279:22765-2272.
10. Sankar S, Mahooti-Brooks N, Centrella M, McCarthy TL, Madri JA. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor β2. J Biol Chem 1995; 270:13567-13572.
11. Cheifetz S, Bellón T, Calés C, et al. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992; 267:19027-19030.
12. Lastres P, Letamendía A, Zhang H, et al. Endoglin modulates cellular responses to TGF-β1. J Cell Biol 1996; 133:1109-1121.
13. Scharpfenecker M, van Dinther M, Liu Z, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007; 120:964-972.
14. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007; 109:1953-1961.
15. David L, Mallet C, Keramidas M, et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res 2008; 102:914-922.
16. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8:464-478.
17. Roberts AB, Anzano MA, Meyers CA, et al. Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry 1983; 22:5692-5698.
18. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-674.
19. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996; 87:1153-1155.
20. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-936.
21. Eguchi M, Masuda H, Asahara T. Endothelial progenitor cells for postnatal vasculogenesis. Clin Exp Nephrol 2007; 11:18-25.
22. Goumans MJ, Mummery C. Functional analysis of the TGFβ receptor/Smad pathway through gene ablation in mice. Int J Dev Biol 2000; 44:253-265.
23. Carvalho RL, Itoh F, Goumans MJ, et al. Compensatory signalling induced in the yolk sac vasculature by deletion of TGFβ receptors in mice. J Cell Sci 2007; 120:4269-4277.
24. Lechleider RJ, Ryan JL, Garrett L, et al. Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. Dev Biol 2001; 240:157-167.
25. Tremblay KD, Dunn NR, Robertson EJ. Mouse embryos lacking Smad1 signals display defects in extra-embryonic tissues and germ cell formation. Development 2001; 128:3609-3621.
26. Lan Y, Liu B, Yao H, et al. Essential role of endothelial Smad4 in vascular remodeling and integrity. Mol Cell Biol 2007; 27:7683-7692.
27. Chang H, Zwijsen A, Vogel H, Huylebroeck D, Matzuk MM. Smad5 is essential for left-right asymmetry in mice. Dev Biol 2000; 219:71-78.
28. Topper JN, Cai J, Qiu Y, et al. Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc Natl Acad Sci USA 1997; 94:9314-9319.
29. Zwijsen A, Goumans MJ, Lawson KA, Van Rooijen MA, Mummery CL. Ectopic expression of the transforming growth factor beta type II receptor disrupts mesoderm organisation during mouse gastrulation. Dev Dyn 1999; 214:141-151.
30. Galvin KM, Donovan MJ, Lynch CA, et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 2000; 24:171-174.
31. Chen Q, Chen H, Zheng D, et al. Smad7 is required for the development and function of heart. J Biol Chem 2008 Oct 24. doi:10.1074/jbc.M807233200.
32. Roelen BA, van Rooijen MA, Mummery CL. Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev Dyn 1997; 4:418-430.
33. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol Cell 2003; 12:817-828.
34. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol. 1996; 134:1563-1571.
35. Watabe T, Nishihara A, Mishima K, et al. TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J Cell Biol 2003; 163:1303-1311.
36. Birukova AA, Adyshev D, Gorshkov B, Birukov KG, Verin AD. ALK5 and Smad4 are involved in TGF-β1-induced pulmonary endothelial permeability. FEBS Lett 2005; 579:4031-4037.
37. Rudini N, Felici A, Giampietro C, et al.VE-cadherin is a critical endothelial regulator of TGF-β signalling. EMBO J 2008; 27:993-1004.
38. Santibanez JF, Blanco FJ, Garrido-Martin EM, Sanz-Rodriguez F, del Pozo MA, Bernabeu C. Caveolin-1 interacts and cooperates with the transforming growth factor-β type I receptor ALK1 in endothelial caveolae. Cardiovasc Res 2008; 77:791-799.
39. Lamouille S, Mallet C, Feige JJ, Bailly S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 2002; 100:4495-4501.
40. Mallet C, Vittet D, Feige JJ, Bailly S. TGFβ1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: respective contribution of ALK1 and ALK5. Stem Cells 2006; 24:2420-2427.
41. Valdimarsdottir G, Goumans MJ, Rosendahl A, et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 2002; 106:2263-2270.
42. Suzuki Y, Montagne K, Nishihara A, Watabe T, Miyazono K. BMPs promote proliferation and migration of endothelial cells via stimulation of VEGF-A/VEGFR2 and angiopoietin-1/Tie2 signalling. J Biochem 2008; 143:199-206.
43. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2004; 2:141-149.
44. Heinke J, Wehofsits L, Zhou Q, et al. BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circ Res 2008; 103:804-812.
45. Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res 2006; 98:209-217.
46. Takahashi K, Kogaki S, Matsushita T, Nasuno S, Kurotobi S, Ozono K. Hypoxia induces alteration of bone morphogenetic protein receptor signaling in pulmonary artery endothelial cell. Pediatr Res 2007; 61:392-397.
47. Cheifetz S, Hernandez H, Laiho M, ten Dijke P, Iwata KK, Massagué J. Distinct transforming growth factor-β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J Biol Chem 1990; 265:20533-20538.
48. Wong SH, Hamel L, Chevalier S, Philip A. Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-β signalling receptors. Eur J Biochem 2000; 267:5550-5560.
49. Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J 2004; 23:4018-4028.
50. Obreo J, Díez-Marques L, Lamas S, et al. Endoglin expression regulates basal and TGF-β1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol Biochem 2004; 14:301-310.
51. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-β receptor complex. J Cell Physiol 2005; 204:574-584.
52. Jerkic M, Rodríguez-Barbero A, Prieto M, et al. Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res 2006; 69:845-854.
53. Li C, Issa R, Kumar P, et al. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 2003; 116:2677-2685.
54. Lee NY, Ray BN, How T, Blobe GC. Endoglin promotes transforming growth factor-β-mediated smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem 2008; 283: 32527-32533 .
55. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003; 22:6557-6563.
56. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003; 17:984-992.
57. Pérez-Gómez E, Eleno N, López-Novoa JM, et al. Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene 2005; 24:4450-4461.
58. Velasco S, Alvarez-Muñoz P, Pericacho M, et al. L- and S-endoglin differentially modulate TGFβ1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci 2008; 121:913-919.
59. Blanco FJ, Grande MT, Langa C, et al. S-Endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ Res 2008; 103:1383-1392.
60. Bobik A.Transforming growth factor-βs and vascular disorders. Arterioscler Thromb Vasc Biol 2006; 26:1712-1720.
61. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995; 75:487-517.
62. Qiu P, Ritchie RP, Fu Z, et al. Myocardin enhances Smad3-mediated transforming growth factor-β1 signaling in a CArG box-independent manner: Smad-binding element is an important cis element for SM22a transcription in vivo. Circ Res 2005; 97:983-991.
63. Nishimura G, Manabe I, Tsushima K, et al. DeltaEF1 mediates TGF-β signaling in vascular smooth muscle cell differentiation. Dev Cell 2006; 11:93-104.
64. Feinberg MW, Watanabe M, Lebedeva MA, et al. Transforming growth factor-β1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem 2004; 279:16388-16393.
65. Wei J, Gorman TE, Liu X, et al. Increased neointima formation in cysteine-rich protein 2-deficient mice in response to vascular injury. Circ Res 2005; 97:1323-1331.
66. Lin DW, Chang IC, Tseng A, et al. Transforming growth factor β up-regulates cysteine-rich protein 2 in vascular smooth muscle cells via activating transcription factor 2. J Biol Chem 2008; 283:15003- 15014.
67. Kobayashi K, Yokote K, Fujimoto M, et al. Targeted disruption of TGF-β-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury. Circ Res 2005; 96:904-912.
68. Mancini ML, Verdi JM, Conley BA, et al. Endoglin is required for myogenic differentiation potential of neural crest stem cells. Dev Biol 2007; 308: 520-533.
69. Willette RN, Gu JL, Lysko PG, Anderson KM, Minehart H, Yue T. BMP-2 gene expression and effects on human vascular smooth muscle cells. J Vasc Res 1999; 36:120-125.
70. Hansmann G, de Jesus Perez VA, Alastalo TP, et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008; 118:1846-1857.
71. Dorai H, Vukicevic S, Sampath TK. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 2000; 184:37-45.
72. Lagna G, Nguyen PH, Ni W, Hata A. BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2006; 291:L1059-1067
73. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008; 454:56-61.
74. Hungerford JE, Owens GK, Argraves WS, Little CD. Development of the aortic vessel wall as defined by vascular smooth muscle and extracellular matrix markers. Dev Biol 1996; 178:375-392.
75. Ding R, Darland DC, Parmacek MS, D'Amore PA. Endothelial-mesenchymal interactions in vitro reveal molecular mechanisms of smooth muscle/pericyte differentiation. Stem Cells Dev 2004; 13:509-520.
76. Arthur HM, Ure J, Smith AJ, et al. Endoglin, an ancillary TGFβ receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000; 217:42-53.
77. Yamamoto T, Kozawa O, Tanabe K, et al. Involvement of p38 MAP kinase in TGF-β-stimulated VEGF synthesis in aortic smooth muscle cells. J Cell Biochem 2001; 82:591-598.
78. Black SM, Grobe A, Mata-Greenwood E, Noskina Y. Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-β1 and reactive oxygen species: a requirement for NAD(P)H oxidase. Conf Proc IEEE Eng Med Biol Soc 2004; 7:5053-5056.
79. Dongmei L, Cuili Z, Song F, Lubenec I, Tian Y, Song QH. VEGF regulates FGF-2 and TGF-β1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration. Microvasc Res 2008 Oct 2. doi: 10.1016/j.mvr.2008.09.007.
80. Kokudo T, Suzuki Y, Yoshimatsu Y, Yamazaki T, Watabe T, Miyazono K. Snail is required for TGFβ-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J Cell Sci 2008; 121:3317-3324.
81. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43:97-110.
82. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8:345-351.
83. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13:189-195.
84. Gallione CJ, Richards JA, Letteboer TG, et al. SMAD4 mutations found in unselected HHT patients. J Med Genet 2006; 43:793-797.
85. Park SO, Lee YJ, Seki T, et al. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 2008; 111:633-642.
86. Bourdeau A, Faughnan ME, McDonald ML, Paterson AD, Wanless IR, Letarte M. Potential role of modifier genes influencing transforming growth factor-β1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol 2001; 158:2011-2020.
87. Robinson PN, Arteaga-Solis E, Baldock C, et al. The molecular genetics of Marfan syndrome and related disorders. J Med Genet 2006; 43:769-787.
88. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33:407-411.
89. Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007; 13:204-210.
90. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312:117-121.
91. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-β receptor. N Engl J Med 2006; 355:788-798.
92. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2003; 37:275-281.
93. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008; 358:2787-2795.
94. Sibai BM. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol 2006; 30:16-19.
95. Levine RJ, Lam C, Qian C, et al. CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992-1005.
96. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642-649.
97. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105:1672-1678.
98. Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999; 155:411-419.
99. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The Interna tional PPH Consortium. Nat Genet 2000; 26:81-84.
100. Machado RD, Aldred MA, James V, et al. Mutations of the TGF-β type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006; 27:121-132.
101. Fujiwara M, Yagi H, Matsuoka R, et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ J 2008; 72:127-133.
102. West J, Fagan K, Steudel W, et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 2004; 94:1109-1114.
103. Yang J, Davies RJ, Southwood M, et al. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ Res 2008; 102:1212-1221.
104. Yu PB, Deng DY, Beppu H, et al. Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J Biol Chem 2008; 283:3877-3888.
105. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131:1917-1928.
106. Bujak M, Ren G, Kweon HJ, et al. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007; 116:2127-2138.
107. Rosenkranz S. TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63:423-432.
108. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75:977-984.
109. Zhou Y, Poczatek MH, Berecek KH, Murphy-Ullrich JE. Thrombospondin 1 mediates angiotensin II induction of TGF-β activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun 2006; 339:633-641.
110. Wang W, Huang XR, Canlas E, et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 2006; 98:1032-1039.
111. Pfeffer JM, Fischer TA, Pfeffer MA. Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction. Annu Rev Physiol 1995; 57:805-826.
112. Devereux RB, Lyle PA. Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension (LIFE) study. Expert Opin Pharmacother 2004; 5:2311-2320.
113. Parker TG, Packer SE, Schneider MD. Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990; 85:507-514.
114. Rosenkranz S, Flesch M, Amann K, et al. Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1. Am J Physiol Heart Circ Physiol 2002; 283:H1253-1262.
115. Goumans MJ, Zonneveld AJ, ten Dijke P. TGFβ-induced endothelial to mesenchymal transition; a switch to cardiac fibrosis? Trends Cardiovasc Med, in press.
116. Larsson J, Goumans MJ, Sjöstrand LJ, et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J 2001; 20:1663-1673.
117. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333:918-924.